Fennec Pharmaceuticals Inc - Understand $fenc stock

$FENC Market Cap: $142.8 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$48.89M

TTM

Gross Margin

94.34%

TTM

Net Earnings

$2.735M

TTM

Current Assets

$62.17M

Q2 2024

Current Liabilities

$7.749M

Q2 2024

Current Ratio

802.32%

Q2 2024

Total Assets

$63.16M

Q2 2024

Total Liabilities

$64.52M

Q2 2024

Book Value

-$1.357M

Q2 2024

Cash

$43.05M

Q2 2024

P/E

52.22

Sep 18, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$21.25M	$1.535M	$0.00	$200.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	1284.5%		-100.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$21.25M	$1.535M	$0.00	$200.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$1.259M	$86.00K
Gross Profit	$19.99M	$1.449M
Gross Profit Margin	94.08%	94.4%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Selling, General & Admin	$32.71M	$20.51M	$12.24M	$12.95M	$7.400M	$5.400M	$5.020M	$2.400M	$1.630M	$2.520M	$1.330M	$1.550M	$1.940M	$3.900M	$1.210M	$3.520M	$3.280M	$2.880M	$2.540M	$6.070M	$2.000M	$1.150M
YoY Change	59.5%	67.51%	-5.47%	75.0%	37.04%	7.57%	109.17%	47.24%	-35.32%	89.47%	-14.19%	-20.1%	-50.26%	222.31%	-65.63%	7.32%	13.89%	13.39%	-58.15%	203.5%	73.91%	8.49%
% of Gross Profit	163.6%	1415.25%
Research & Development	$56.00K	$3.531M	$4.981M	$5.105M	$5.610M	$5.008M	$1.936M	$472.0K	$256.0K	$357.0K	$579.0K	$2.075M	$1.490M	$710.0K	$2.110M	$10.37M	$10.91M	$14.00M	$11.68M	$6.940M	$2.750M	$2.760M
YoY Change	-98.41%	-29.11%	-2.43%	-9.0%	12.02%	158.68%	310.17%	84.38%	-28.29%	-38.34%	-72.1%	39.26%	109.86%	-66.35%	-79.65%	-4.95%	-22.07%	19.86%	68.3%	152.36%	-0.36%	44.5%
% of Gross Profit	0.28%	243.69%
Depreciation & Amortization											$0.00	$0.00	$0.00	$0.00	$0.00	$160.0K	$80.00K	$90.00K	$220.0K	$3.840M	$1.500M	$180.0K
YoY Change															-100.0%	100.0%	-11.11%	-59.09%	-94.27%	156.0%	733.33%
% of Gross Profit
Operating Expenses	$32.76M	$24.04M	$17.22M	$18.06M	$13.01M	$5.008M	$1.936M	$472.0K	$256.0K	$357.0K	$579.0K	$2.075M	$3.440M	$4.600M	$3.330M	$13.89M	$14.19M	$16.89M	$14.22M	$16.57M	$6.010M	$3.910M
YoY Change	36.3%	39.57%	-4.61%	38.78%	159.78%	158.68%	310.17%	84.38%	-28.29%	-38.34%	-72.1%	-39.68%	-25.22%	38.14%	-76.03%	-2.11%	-15.99%	18.78%	-14.18%	175.71%	53.71%	31.65%
Operating Profit	-$12.77M	-$22.59M	-$17.22M	-$17.89M		-$10.41M	-$6.951M	-$2.871M	-$1.890M	-$2.877M	-$1.931M	-$3.620M
YoY Change	-43.46%	31.16%	-3.7%			49.75%	142.11%	51.9%	-34.31%	48.99%	-46.66%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Interest Expense	-$3.274M	-$1.125M	-$123.0K	-$220.0K	$250.0K	$520.0K	-$90.00K	$60.00K	$1.230M	$700.0K	$0.00	$0.00	$8.120M	-$3.220M	$200.0K	$290.0K	$830.0K	$450.0K	$350.0K	-$10.00K	$60.00K	$310.0K
YoY Change	191.02%	814.63%	-44.09%	-188.0%	-51.92%	-677.78%	-250.0%	-95.12%	75.71%			-100.0%	-352.17%	-1710.0%	-31.03%	-65.06%	84.44%	28.57%	-3600.0%	-116.67%	-80.65%	63.16%
% of Operating Profit
Other Income/Expense, Net	-$3.274M	-$1.125M	-$123.0K	-$224.0K	-$20.00K	$521.0K	-$95.00K	$82.00K	$1.231M	$701.0K	$3.776M	-$1.543M
YoY Change	191.02%	814.63%	-45.09%	1020.0%	-103.84%	-648.42%	-215.85%	-93.34%	75.61%	-81.44%	-344.72%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Pretax Income	-$16.05M	-$10.55M	-$9.122M	-$8.784M	-$12.78M	-$7.702M	-$7.046M	-$2.789M	-$658.0K	-$1.327M	$2.620M	-$5.160M	$4.690M	-$7.820M	-$3.010M	-$13.60M	-$13.36M	-$16.44M	-$13.87M	-$17.81M	-$5.950M	-$3.600M
YoY Change	52.11%	15.63%	3.85%	-31.27%	65.93%	9.31%	152.64%	323.86%	-50.41%	-150.65%	-150.78%	-210.02%	-159.97%	159.8%	-77.87%	1.8%	-18.73%	18.53%	-22.12%	199.33%	65.28%	29.5%
Income Tax		$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	-$1.300M	-$460.0K	$0.00
% Of Pretax Income											0.0%		0.0%
Net Earnings	-$16.05M	-$23.71M	-$17.35M	-$18.11M	-$12.78M	-$9.888M	-$7.046M	-$2.789M	-$659.0K	-$2.176M	$1.845M	-$5.163M	$4.685M	-$7.824M	-$3.012M	-$13.60M	-$13.36M	-$16.44M	-$13.87M	-$6.872M	-$17.80M	-$3.732M
YoY Change	-32.34%	36.71%	-4.21%	41.7%	29.25%	40.33%	152.64%	323.22%	-69.72%	-217.94%	-135.74%	-210.2%	-159.88%	159.76%	-77.85%	1.82%	-18.75%	18.52%	101.85%	-61.38%	376.82%	47.86%
Net Earnings / Revenue	-75.5%	-1544.89%		-9054.5%
Basic Earnings Per Share	-$0.60	-$0.90	-$0.67	-$0.76					-$0.06	-$0.22	$0.19	-$0.21
Diluted Earnings Per Share	-$0.60	-$0.90	-$0.67	-$0.76	-$642.2K	-$522.2K	-$469.7K	-$218.5K	-$0.06	-$0.22	$0.17	-$0.21	$584.8K	-$1.464M	-$1.270M	-$5.738M	-$6.185M	-$18.68M	-$19.00M	-$19.93M	-$74.17M	-$24.87M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Cash & Short-Term Investments	$13.27M	$23.77M	$21.10M	$30.34M	$13.65M	$22.78M	$28.26M	$3.930M	$940.0K	$2.310M	$1.660M	$2.300M	$5.300M	$5.950M	$690.0K	$5.350M	$16.16M	$5.670M	$13.09M	$17.48M	$2.150M
YoY Change	-44.19%	12.67%	-30.45%	122.27%	-40.08%	-19.39%	619.08%	318.09%	-59.31%	39.16%	-27.83%	-56.6%	-10.92%	762.32%	-87.1%	-66.89%	185.01%	-56.68%	-25.11%	713.02%
Cash & Equivalents	$11.93M	$23.77M	$21.10M	$30.34M	$13.65M	$22.78M	$28.26M	$3.930M	$940.0K	$2.310M	$1.660M	$2.300M	$5.300M	$5.950M	$690.0K	$5.350M	$16.16M	$5.670M	$11.92M	$17.48M	$2.150M
Short-Term Investments																			$1.180M	$0.00	$0.00
Other Short-Term Assets	$2.619M	$833.0K	$1.287M	$1.080M	$240.0K	$170.0K	$140.0K	$40.00K	$80.00K	$70.00K	$90.00K	$70.00K	$60.00K	$50.00K	$80.00K	$150.0K	$210.0K	$130.0K	$170.0K	$170.0K	$760.0K
YoY Change	214.41%	-35.28%	19.17%	350.0%	41.18%	21.43%	250.0%	-50.0%	14.29%	-22.22%	28.57%	16.67%	20.0%	-37.5%	-46.67%	-28.57%	61.54%	-23.53%	0.0%	-77.63%
Inventory	$2.156M	$576.0K
Prepaid Expenses
Receivables	$8.814M	$1.545M												$0.00	$70.00K	$10.00K	$20.00K	$30.00K	$20.00K	$20.00K	$20.00K
Other Receivables	$0.00	$0.00												$0.00	$0.00	$130.0K	$170.0K	$70.00K	$120.0K	$250.0K	$400.0K
Total Short-Term Assets	$26.86M	$26.73M	$22.39M	$31.42M	$13.88M	$22.95M	$28.40M	$3.970M	$1.020M	$2.370M	$1.750M	$2.370M	$5.350M	$5.990M	$830.0K	$5.640M	$16.56M	$5.900M	$13.40M	$17.92M	$3.330M
YoY Change	0.49%	19.39%	-28.75%	126.37%	-39.52%	-19.19%	615.37%	289.22%	-56.96%	35.43%	-26.16%	-55.7%	-10.68%	621.69%	-85.28%	-65.94%	180.68%	-55.97%	-25.22%	438.14%
Property, Plant & Equipment															$0.00	$140.0K	$290.0K	$290.0K	$370.0K	$650.0K	$490.0K
YoY Change															-100.0%	-51.72%	0.0%	-21.62%	-43.08%	32.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.000K	$211.0K	$27.00K	$0.00	$260.0K										$0.00	$290.0K	$360.0K	$440.0K	$520.0K	$10.00K	$120.0K
YoY Change	-97.16%	681.48%		-100.0%											-100.0%	-19.44%	-18.18%	-15.38%	5100.0%	-91.67%
Total Long-Term Assets	$6.000K	$211.0K	$27.00K	$0.00	$270.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$420.0K	$650.0K	$730.0K	$15.05M	$21.09M	$22.34M
YoY Change	-97.16%	681.48%		-100.0%											-100.0%	-35.38%	-10.96%	-95.15%	-28.64%	-5.6%
Total Assets	$26.86M	$26.94M	$22.41M	$31.42M	$14.15M	$22.95M	$28.40M	$3.970M	$1.020M	$2.370M	$1.750M	$2.370M	$5.350M	$5.990M	$830.0K	$6.060M	$17.21M	$6.630M	$28.45M	$39.01M	$25.67M
YoY Change
Accounts Payable	$3.778M	$2.390M	$777.0K	$1.570M	$1.610M	$1.030M	$860.0K	$240.0K	$300.0K	$310.0K	$210.0K	$260.0K	$340.0K	$270.0K	$320.0K	$550.0K	$530.0K	$2.070M	$1.390M
YoY Change	58.08%	207.59%	-50.51%	-2.48%	56.31%	19.77%	258.33%	-20.0%	-3.23%	47.62%	-19.23%	-23.53%	25.93%	-15.63%	-41.82%	3.77%	-74.4%	48.92%
Accrued Expenses	$3.775M	$2.219M	$877.0K	$780.0K	$660.0K	$610.0K	$620.0K	$130.0K	$90.00K	$130.0K	$130.0K	$420.0K	$50.00K	$200.0K	$70.00K	$1.880M	$1.830M	$2.620M	$1.280M
YoY Change	70.12%	153.02%	12.44%	18.18%	8.2%	-1.61%	376.92%	44.44%	-30.77%	0.0%	-69.05%	740.0%	-75.0%	185.71%	-96.28%	2.73%	-30.15%	104.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.553M	$4.609M	$1.654M	$2.350M	$2.270M	$1.640M	$1.640M	$400.0K	$470.0K	$1.760M	$3.210M	$7.320M	$5.470M	$10.92M	$420.0K	$2.430M	$2.400M	$4.700M	$2.660M	$1.780M	$1.090M
YoY Change	63.88%	178.66%	-29.62%	3.52%	38.41%	0.0%	310.0%	-14.89%	-73.3%	-45.17%	-56.15%	33.82%	-49.91%	2500.0%	-82.72%	1.25%	-48.94%	76.69%	49.44%	63.3%
Long-Term Debt	$30.00M	$25.00M	$5.000M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.180M
YoY Change	20.0%	400.0%																		-100.0%
Other Long-Term Liabilities	$933.0K	-$101.0K	-$12.00K											$0.00	$10.00K	$580.0K	$660.0K	$670.0K	$550.0K	$140.0K	$140.0K
YoY Change	-1023.76%	741.67%												-100.0%	-98.28%	-12.12%	-1.49%	21.82%	292.86%	0.0%
Total Long-Term Liabilities	$30.93M	$24.90M	$4.988M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$10.00K	$580.0K	$660.0K	$670.0K	$550.0K	$140.0K	$1.320M
YoY Change	24.23%	399.18%												-100.0%	-98.28%	-12.12%	-1.49%	21.82%	292.86%	-89.39%
Total Liabilities	$38.49M	$29.51M	$6.642M	$2.350M	$2.270M	$1.640M	$1.640M	$400.0K	$470.0K	$1.760M	$3.210M	$7.320M	$5.470M	$10.92M	$430.0K	$3.010M	$3.060M	$5.360M	$8.390M	$9.390M	$10.35M
YoY Change	30.43%	344.26%	182.64%	3.52%	38.41%	0.0%	310.0%	-14.89%	-73.3%	-45.17%	-56.15%	33.82%	-49.91%	2439.53%	-85.71%	-1.63%	-42.91%	-36.11%	-10.65%	-9.28%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Basic Shares Outstanding	26.57M	26.28M	26.01K	23.70K	19.90M	18.94M	15.01M	12.77M shares	10.83M shares	9.871M shares	9.719M shares	25.16M shares
Diluted Shares Outstanding	26.57M	26.28M	26.01K	23.70K		18.94M	15.01M	12.77M shares	10.83M shares	9.871M shares	10.57M shares	25.16M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $142.82 Million

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Industry: Biological Products, (No Diagnostic Substances) Peers: Actinium Pharmaceuticals Inc Acumen Pharmaceuticals Inc Lineage Cell Therapeutics Inc Clene Inc. Compass Therapeutics Inc. Gritstone bio Inc VBI Vaccines Inc Viking Therapeutics Inc XOMA Royalty Corp